Johnson & Johnson JNJ
13 of 22 tests passed across all three checklists. These are separate views of the same company, not one rating; see each checklist below.
Johnson & Johnson (JNJ), in the Health Care sector, currently passes 2 of 6 Buffett-inspired tests, 7 of 7 Trend Template-inspired tests (1 not evaluated) and 4 of 9 F-score-inspired tests.
On the Buffett-inspired quality & value checklist it passes on gross margin above 40% and positive free cash flow (5 years), but falls short on ROE above 15% for 10 straight years, debt-to-equity below 0.5 and consistent EPS growth. Lowest return on equity in the last 10 fiscal years was 2.0% (FY2017); needs every year above 15.0%.
On the Minervini Trend Template-inspired checklist, JNJ clears every test we could evaluate.
On the Piotroski F-score-inspired checklist it passes on positive return on assets, positive operating cash flow and return on assets improved among others, but falls short on cash flow exceeds net income, long-term debt ratio fell and current ratio improved. Operating cash flow was 13.6% of assets versus net income at 14.9%; cash needs to come in above reported profit.
Over FY2016–FY2025, revenue went from $71.89B to $94.19B (3.0% a year) and net income from $16.54B to $26.80B.
Buffett-inspired quality & value: 2 of 6 tests passed
Fundamentals from the FY2025 annual report (year ended 28 December 2025). How the Buffett-inspired checklist works →
| Test | Value | Needs | Result |
|---|---|---|---|
| ROE above 15% for 10 straight yearsLowest return on equity in the last 10 fiscal years was 2.0% (FY2017); needs every year above 15.0%. | 2.0% | > 15.0% | Fail |
| Debt-to-equity below 0.5Total debt of $47.93B against shareholders' equity of $81.54B gives 0.59; needs below 0.50. | 0.59 | < 0.50 | Fail |
| Consistent EPS growthDiluted EPS fell in 4 of the last 10 years (max 2) and grew 7.2% a year overall, from $5.48 (FY2015) to $11.03 (FY2025). | 4 | <= 2 | Fail |
| Gross margin above 40%Gross profit was 67.9% of revenue in FY2025; needs above 40.0%. | 67.9% | > 40.0% | Pass |
| Positive free cash flow (5 years)Weakest free cash flow (operating cash flow minus capex) in the last 5 years was $17.18B (FY2022); needs every year above zero. | $17.18B | > $0.00 | Pass |
| Price at or below owner-earnings valueMarket value $641.07B is 2.17x the $294.75B you get by capitalising owner earnings of $29.48B at 10.0%; needs 1.00x or less. | 2.17x | <= 1.00x | Fail |
Minervini Trend Template-inspired: 7 of 7 tests passed
Based on daily closing prices to 26 October 2026. How the Trend Template-inspired checklist works →
| Test | Value | Needs | Result |
|---|---|---|---|
| Price above the 150-day and 200-day averagesClose of $266.30 is +6.8% above the higher of the 150-day ($249.44) and 200-day ($245.31) averages; needs to be above both. | +6.8% | > 0 | Pass |
| 150-day average above 200-day average150-day average $249.44 is +1.7% versus the 200-day $245.31; needs to be above it. | +1.7% | > 0 | Pass |
| 200-day average rising for at least a month200-day average moved +2.4% over the last 22 trading days ($239.47 to $245.31); needs to be rising. | +2.4% | > 0 | Pass |
| 50-day average above the 150-day and 200-day50-day average $265.32 is +6.4% above the higher of the 150-day and 200-day; needs to be above both. | +6.4% | > 0 | Pass |
| Price above the 50-day averageClose of $266.30 is +0.4% versus the 50-day average of $265.32; needs to be above it. | +0.4% | > 0 | Pass |
| At least 30% above the 52-week lowClose of $266.30 is 43.2% above the 52-week low of $186.00; needs at least 30.0%. | 43.2% | >= 30.0% | Pass |
| Within 25% of the 52-week highClose of $266.30 is 4.4% below the 52-week high of $278.43; needs to be within 25.0%. | 4.4% | <= 25.0% | Pass |
| Relative strength rank 70 or higherNot evaluated: ranking needs at least 50 stocks; this run loaded 5. | n/a | >= 70 | n/a |
Piotroski F-score-inspired: 4 of 9 tests passed
Fundamentals from the FY2025 annual report (year ended 28 December 2025). How the F-score-inspired checklist works →
| Test | Value | Needs | Result |
|---|---|---|---|
| Positive return on assetsNet income was 14.9% of beginning-of-year total assets in FY2025; needs to be positive. | 14.9% | > 0.0% | Pass |
| Positive operating cash flowOperating cash flow was $24.53B in FY2025; needs to be positive. | $24.53B | > $0.00 | Pass |
| Return on assets improvedReturn on assets went from 8.4% to 14.9% (FY2024 to FY2025); needs to rise. | +6.5 pts | > 0 | Pass |
| Cash flow exceeds net incomeOperating cash flow was 13.6% of assets versus net income at 14.9%; cash needs to come in above reported profit. | -1.3 pts | > 0 | Fail |
| Long-term debt ratio fellLong-term debt went from 17.6% to 20.8% of average total assets (FY2024 to FY2025); needs to fall. | +3.2 pts | < 0 | Fail |
| Current ratio improvedCurrent ratio went from 1.11 to 1.03 (FY2024 to FY2025); needs to rise. | -0.08 | > +0.00 | Fail |
| No new shares issuedDiluted share count changed +0.0% (FY2024 to FY2025); needs no increase. | +0.0% | <= 0 | Pass |
| Gross margin improvedGross margin went from 69.1% to 67.9% (FY2024 to FY2025); needs to rise. | -1.2 pts | > 0 | Fail |
| Asset turnover improvedRevenue per dollar of beginning assets went from 0.53 to 0.52 (FY2024 to FY2025); needs to rise. | -0.01 | > +0.00 | Fail |
JNJ ten-year fundamentals
From Johnson & Johnson's 10-K filings. ROE uses average shareholders' equity; free cash flow is operating cash flow minus capital expenditure; EPS is diluted and restated for any stock splits onto today's share basis.
| FY | Revenue | Net income | EPS | Gross margin | ROE | Free cash flow | Debt/equity |
|---|---|---|---|---|---|---|---|
| 2025 | $94.19B | $26.80B | $11.03 | 67.9% | 35.0% | $19.70B | 0.59 |
| 2024 | $88.82B | $14.07B | $5.79 | 69.1% | 20.1% | $19.84B | 0.51 |
| 2023 | $85.16B | $35.15B | $13.72 | 68.8% | 48.3% | $18.25B | 0.43 |
| 2022 | $79.99B | $17.94B | $6.73 | 69.3% | 23.8% | $17.18B | 0.52 |
| 2021 | $78.74B | $20.88B | $7.81 | 70.3% | 30.4% | $19.76B | 0.46 |
| 2020 | $82.58B | $14.71B | $5.51 | 65.6% | 24.0% | $20.19B | 0.56 |
| 2019 | $82.06B | $15.12B | $5.63 | 66.4% | 25.4% | $19.92B | 0.47 |
| 2018 | $81.58B | $15.30B | $5.61 | 66.8% | 25.5% | $18.53B | 0.51 |
| 2017 | $76.45B | $1.30B | $0.47 | 66.7% | 2.0% | $17.78B | 0.57 |
| 2016 | $71.89B | $16.54B | $5.93 | 69.7% | 23.4% | $15.54B | 0.39 |
How to read these results
Each checklist turns a published investing approach into yes/no tests. A pass means JNJ met that one threshold on the latest data; it doesn't mean the stock is cheap, safe or likely to rise. The fundamental tests use Johnson & Johnson's annual reports, so they change only when a new 10-K is filed. The trend tests use daily closing prices and can flip from one day to the next.
"n/a" means the data needed wasn't available. Common reasons are a company that doesn't report a figure (banks, for example, have no gross margin) or not enough years of history. Those tests are left out of the score rather than counted as fails.
Data comes from Johnson & Johnson's SEC filings (latest 10-K filed 11 February 2026) and Marketstack end-of-day prices. Last updated 26 October 2026.